Clinical Trials Logo
  1. Home
  2. Breakthrough Cancer Pain
  3. NCT05531422

Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP

Breakthrough Cancer Pain Clinical Trial

Official title:
Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With BTcP

Clinical Trial Summary

Breakthrough cancer pain (BTcP) is a common problem in patients with cancer. This is a phase IIa dose-response and safety study of inhaled fentanyl aerosol (25µg/dose) in Chinese patients with breakthrough cancer pain.

Clinical Trial Description

Consenting patients who met inclusion and exclusion criteria were allowed to enter the study. The medication for background pain during screening were maintained until the end of the study. Each patient would be treated and observed for 6 episodes of targeted BTcP. Patients were randomly assigned to 1 of the 6 prespecified dose sequences which were established by a computer-generated schedule of active drug and placebo in a 4:2 ratio. All patients and personnel involved with the study (including investigators and investigation site personnel) were blinded to the medication codes. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05531422
Study type Interventional
Source Lee's Pharmaceutical Limited
Contact
Status Completed
Phase Phase 2
Start date October 20, 2021
Completion date April 27, 2023
View Details
See also
  Status Clinical Trial Phase
Completed NCT01946555 - Prospective Longitudinal Observational Study to Evaluate the Clinical Characteristics and Opioids Treatments in Patients With Breakthrough Cancer Pain N/A
Recruiting NCT01693328 - Patient Satisfaction and Quality of Life Impact - PecFent® N/A
Recruiting NCT01698645 - Patient Satisfaction and Quality of Life Impact - PecFent® N/A
Completed NCT01936636 - Observational Registry Study of Quality of Life When Treating BTcP With Abstral N/A
Completed NCT03669263 - A Dose Titration Study of Fentanyl Buccal Soluble Film for Breakthrough Cancer Pain in Taiwan N/A
Completed NCT02899884 - Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain
Recruiting NCT03564548 - Inhaled Cannabinoids Versus Immediate-release Oral Opioids for the Management of Breakthrough Cancer Pain Phase 2
Not yet recruiting NCT04713189 - Effectiveness and Tolerance of Inhaled Fentanyl Aerosol (25µg/Dose) in Chinese Patients With Breakthrough Cancer Pain Phase 1/Phase 2
Completed NCT03895762 - Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients
Terminated NCT01439919 - A Clinical Trial to Assess the Clinical Benefit of SSR411298 as Adjunctive Treatment for Persistent Cancer Pain Phase 2
Completed NCT01045603 - Instanyl® Non-Interventional Study N/A
Recruiting NCT00822614 - Safety of Fentanyl TAIFUN Treatment Phase 3
Terminated NCT04468490 - Treatment of Breakthrough Cancer Pain According to European Guidelines